Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880410 · ClinicalTrials.gov registry record · Phase 1
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Monteris Medical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02880410: Clinical Trial Phase 1 study, sponsored by Monteris Medical.
NCT02880410 is a Phase 1 study that was terminated before completion, run by Monteris Medical. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02880410, a Phase 1 study, was terminated before completion, sponsored by Monteris Medical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation therapy and temozolomide for the treatment of newly diagnosed glioblastomas (GBM).
Primary Outcome
Characterize adverse events experienced in glioblastoma subjects undergoing LITT using the NeuroBlate System. Adverse events will be collected based on subject reports and subject examination/testing.
Interventions
- DEVICE NeuroBlate System
- DRUG Radiation therapy and temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2018-09-14 |
| Phase | Phase 1 |
Why NCT02880410 stopped before completion
NCT02880410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which NeuroBlate System is the first listed.
NCT02880410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02880410 about?
NCT02880410 is a clinical study titled "Feasibility Study on LITT for Newly Diagnosed Glioblastoma". Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation therapy and temozolomide for the treatment of newly diagnosed glioblasto...
What is the current status of trial NCT02880410?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-08-15. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT02880410?
The interventions under investigation include: NeuroBlate System (DEVICE), Radiation therapy and temozolomide (DRUG).
Who is sponsoring clinical trial NCT02880410?
This trial is sponsored by Monteris Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02880410's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI